Gene · 2931
Papers2,889
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
181 to 200 of 2,889
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients. | Genes Dis | 2023 | 37397537 | PubTator, text mining | PubMed |
| Towards a More Comprehensive Picture of the MicroRNA-23a/b-3p Impact on Impaired Male Fertility. | Biology (Basel) | 2023 | 37372085 | PubTator, text mining | PubMed |
| Targeting Pro-Survival Autophagy Enhanced GSK-3β Inhibition-Induced Apoptosis and Retarded Proliferation in Bladder Cancer Cells. | Curr Oncol | 2023 | 37366889 | PubTator, text mining | PubMed |
| An optogenetic-phosphoproteomic study reveals dynamic Akt1 signaling profiles in endothelial cells. | Nat Commun | 2023 | 37365174 | PubTator, text mining | PubMed |
| Transducing compressive forces into cellular outputs in cancer and beyond. | Life Sci Alliance | 2023 | 37364915 | PubTator, text mining | PubMed |
| New insights on the potential effect of vinpocetine in Parkinson's disease: one of the neglected warden and baffling topics. | Metab Brain Dis | 2023 | 37335452 | PubTator, text mining | PubMed |
| Elucidating Fibroblast Growth Factor-Induced Kinome Dynamics Using Targeted Mass Spectrometry and Dynamic Modeling. | Mol Cell Proteomics | 2023 | 37328066 | PubTator, text mining | PubMed |
| Elraglusib (formerly 9-ING-41) possesses potent anti-lymphoma properties which cannot be attributed to GSK3 inhibition. | Cell Commun Signal | 2023 | 37316860 | PubTator, text mining | PubMed |
| Differential effect of lactate on synovial fibroblast and macrophage effector functions. | Front Immunol | 2023 | 37304267 | PubTator, text mining | PubMed |
| Regulation of PD-L1 Trafficking from Synthesis to Degradation. | Cancer Immunol Res | 2023 | 37290119 | PubTator, text mining | PubMed |
| Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment. | Breast Cancer Res | 2023 | 37280713 | PubTator, text mining | PubMed |
| Possible involvement of Interleukin-17A in the deterioration of prepulse inhibition on acoustic startle response in mice. | Neuropsychopharmacol Rep | 2023 | 37280178 | PubTator, text mining | PubMed |
| Insulin signalling and GLUT4 trafficking in insulin resistance. | Biochem Soc Trans | 2023 | 37248992 | PubTator, text mining | PubMed |
| A Chemical Proteomics Approach to Discover Regulators of Innate Immune Signaling. | Viruses | 2023 | 37243198 | PubTator, text mining | PubMed |
| In Silico-Motivated Discovery of Novel Potent Glycogen Synthase-3 Inhibitors: 1-(Alkyl/arylamino)-3H-naphtho[1,2,3-de]quinoline-2,7-dione Identified as a Scaffold for Kinase Inhibitor Development. | Pharmaceuticals (Basel) | 2023 | 37242443 | PubTator, text mining | PubMed |
| PD-L1: expression regulation. | Blood Sci | 2023 | 37228770 | PubTator, text mining | PubMed |
| Regulation of hematopoietic stem cells differentiation, self-renewal, and quiescence through the mTOR signaling pathway. | Front Cell Dev Biol | 2023 | 37228652 | PubTator, text mining | PubMed |
| Long-chain polyphosphates inhibit type I interferon signaling and augment LPS-induced cytokine secretion in human leukocytes. | J Leukoc Biol | 2023 | 37224571 | PubTator, text mining | PubMed |
| AZD5438 a GSK-3a/b and CDK inhibitor is antiapoptotic modulates mitochondrial activity and protects human neurons from mitochondrial toxins. | Sci Rep | 2023 | 37221196 | PubTator, text mining | PubMed |
| Iron metabolism and ferroptosis in diabetic bone loss: from mechanism to therapy. | Front Nutr | 2023 | 37215218 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2931/papers?page=10